Pimobendan, spironolactone, digoxin, sotalol tell me about their usage and their dose rate in dog and cat according to plums and others books
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching the Web
Plumb's veterinary drug handbook pimobendan spironolactone digoxin sotalol dog cat dose
Searching PubMed
pimobendan dog cat cardiac dose
Library note: The medical textbook library available to me contains only human medicine textbooks (no Plumb's, Ettinger, or veterinary titles). The comprehensive answer above is drawn from my training on those veterinary references directly.
Cardiovascular Drug Reference: Dogs & Cats
1. Pimobendan (Vetmedin®)
Mechanism of Action
A benzimidazole-pyridazinone with two synergistic mechanisms:
- Calcium sensitizer — increases myofilament sensitivity to Ca²⁺ → positive inotropy without raising intracellular Ca²⁺ (no increase in myocardial O₂ demand)
- PDE-3 inhibitor — reduces cAMP breakdown → arterial and venous vasodilation (reduces afterload and preload)
Net effect: improves contractility, promotes relaxation, and reduces cardiac workload simultaneously.
Indications
| Species | Indication |
|---|---|
| Dog | MVD stage B2 (preclinical with cardiomegaly, per ACVIM 2019 consensus); MVD/DCM stages C & D (CHF); systolic dysfunction |
| Cat | Systolic dysfunction; end-stage HCM; restrictive/unclassified CM — off-label |
The EPIC Trial (Boswood et al., 2016) established pimobendan in preclinical MVD (B2 dogs), delaying CHF onset by a median of ~15 months vs. placebo.
Dose Rates
Dog:
| Dose | Frequency | Notes |
|---|---|---|
| 0.25–0.3 mg/kg | BID (q12h) | Total daily dose 0.5–0.6 mg/kg |
| 0.3 mg/kg | q8h initially (acute decompensation) | Then step down to BID |
- Give on empty stomach (1 h before or 2 h after food) — food ↓ bioavailability ~30%
- Round dose to nearest tablet size: 1.25 mg / 2.5 mg / 5 mg / 10 mg
Cat:
| Dose | Frequency | Notes |
|---|---|---|
| 1.25 mg/cat (flat dose) | BID | Off-label |
| 0.625–1.25 mg/cat | SID–BID | Lower end for small cats |
- Contraindicated in hypertrophic obstructive cardiomyopathy (HOCM) — worsens LVOTO
- Avoid in aortic or pulmonic stenosis with preserved systolic function
2. Spironolactone (Aldactone®)
Mechanism of Action
Competitive aldosterone antagonist at mineralocorticoid receptors in the renal collecting duct → promotes Na⁺/water excretion while retaining K⁺ (potassium-sparing diuretic).
Additional cardiac benefits beyond diuresis:
- Anti-fibrotic effect on myocardium → reduces ventricular remodeling
- Counteracts aldosterone escape (breakthrough aldosterone secretion that occurs with chronic furosemide + ACEi therapy)
Indications
| Species | Indication |
|---|---|
| Dog | CHF adjunct (MVD, DCM) alongside furosemide + ACEi ± pimobendan; primary hyperaldosteronism; refractory ascites |
| Cat | Primary hyperaldosteronism (adrenal tumor — most common indication in cats); CHF adjunct |
The QUEST trial (2007) suggested a survival benefit with spironolactone (2 mg/kg/day) added to standard CHF therapy in MVD dogs.
Dose Rates
Dog:
| Indication | Dose | Frequency |
|---|---|---|
| CHF / cardioprotection | 2 mg/kg | SID or divided BID |
| Hyperaldosteronism | 1–2 mg/kg | BID |
Cat:
| Indication | Dose | Frequency |
|---|---|---|
| Primary hyperaldosteronism | 2–4 mg/kg | BID |
| CHF adjunct | 1–2 mg/kg | SID–BID |
Key Adverse Effects
- Hyperkalemia — monitor K⁺ at baseline, 5–7 days, then monthly; especially dangerous with ACEi/ARBs
- Azotemia — monitor BUN/Cr
- ⚠️ Cats: ulcerative facial dermatitis — a unique, serious cutaneous drug reaction; inspect facial skin at each recheck; discontinue immediately if lesions appear
- Gynecomastia (rare, dogs)
3. Digoxin (Lanoxin®)
Mechanism of Action
A cardiac glycoside with two mechanisms:
- Positive inotropy — inhibits Na⁺/K⁺-ATPase → intracellular Na⁺ ↑ → Na⁺/Ca²⁺ exchanger reversal → intracellular Ca²⁺ ↑ → stronger contraction
- Negative chronotropy / vagomimetic — increases vagal tone → slows AV nodal conduction → reduces ventricular rate in AF
Indications
| Species | Indication |
|---|---|
| Dog | Atrial fibrillation (rate control); SVT; CHF adjunct (weak inotrope, largely superseded by pimobendan but still used for AF) |
| Cat | SVT, AF — used very rarely due to extreme sensitivity and narrow therapeutic index |
Dose Rates
Dog:
| Dose | Frequency | Notes |
|---|---|---|
| 0.005–0.011 mg/kg (5–11 µg/kg) | BID | Use lean body weight |
| Maximum: 0.375 mg/dog/day total | — | Never exceed regardless of body weight |
| Alternatively: 0.22 mg/m² BSA | BID | Useful for large/giant breeds |
- Large/giant breeds: use lower end (0.005 mg/kg BID)
- Elixir (0.05 mg/mL) preferred — better and more consistent absorption than tablets
- Check serum level 6–8 hours post-dose at day 7–10: therapeutic range 0.8–2.0 ng/mL; toxic >2.5 ng/mL
Cat:
| Dose | Frequency | Notes |
|---|---|---|
| 0.007–0.01 mg/kg | q48h | Cats metabolize digoxin very slowly |
| ≈ 0.031 mg/cat (¼ of 0.125 mg tablet) | q48h | For ~4 kg average cat |
- Use elixir for accurate dosing
- Therapeutic range: 0.9–2.0 ng/mL (sample 8–10 hours post-dose)
- Many veterinary cardiologists avoid digoxin in cats entirely due to toxicity risk
Key Adverse Effects & Toxicity
- Narrow therapeutic index — toxicity common
- GI: anorexia, vomiting, diarrhea (often first signs)
- Cardiac: bradycardia, AV block, ventricular arrhythmias
- Neurological: lethargy, disorientation (especially cats)
- Predisposing factors for toxicity: hypokalemia, hypomagnesemia, renal insufficiency, hypothyroidism
- Treatment: discontinue drug, correct electrolytes; digoxin-specific Fab antibodies (Digibind/DigiFab) for life-threatening toxicity
Critical Drug Interactions:
- Quinidine, verapamil, amiodarone, tetracyclines → ↑ serum digoxin levels (reduce digoxin dose by ~50% if co-administered)
4. Sotalol (Betapace®)
Mechanism of Action
A mixed Class II + Class III antiarrhythmic:
- Class II (beta-blocker) — L-isomer blocks β₁/β₂ adrenergic receptors → ↓ automaticity, ↓ HR, ↓ AV conduction velocity
- Class III (K⁺ channel blocker) — both isomers block the rapid delayed rectifier K⁺ current (I_Kr) → prolongs action potential duration and refractory period → suppresses re-entrant ventricular and supraventricular arrhythmias
Indications
| Species | Indication |
|---|---|
| Dog | Ventricular tachycardia (primary drug for Boxer ARVC, German Shepherd VT); AF; SVT; prevention of sudden cardiac death in arrhythmogenic cardiomyopathy |
| Cat | Ventricular arrhythmias; HCM-associated arrhythmias; SVT |
Sotalol is one of the most commonly used antiarrhythmics in veterinary cardiology, particularly for Boxer ARVC where it effectively reduces ventricular ectopy burden on Holter monitoring.
Dose Rates
Dog:
| Dose | Frequency | Notes |
|---|---|---|
| 1–3.5 mg/kg | BID | Start low, titrate up |
| Common starting dose: 1–2 mg/kg | BID | Guide titration by Holter + clinical response |
Cat:
| Dose | Frequency | Notes |
|---|---|---|
| 1–2 mg/kg | BID | Start at 1 mg/kg |
Key Adverse Effects
- QT prolongation → Torsades de Pointes (TdP) — most serious risk; monitor ECG (QTc) at baseline and after dose increases; if QTc prolongs >25% above baseline, reduce dose
- Bradycardia, hypotension
- Negative inotropy — use with great caution or avoid in CHF/systolic dysfunction
- Bronchoconstriction — avoid in animals with reactive airway disease
- Contraindications: pre-existing AV block, severe bradycardia, uncompensated heart failure, hypokalemia/hypomagnesemia (↑ TdP risk)
Summary Table
| Drug | Class | Primary Use — Dog | Primary Use — Cat | Dog Dose | Cat Dose |
|---|---|---|---|---|---|
| Pimobendan | Ca²⁺ sensitizer + PDE-3i | MVD (B2–D), DCM, CHF | Systolic dysfunction (off-label) | 0.25–0.3 mg/kg PO BID | 1.25 mg/cat PO BID |
| Spironolactone | Aldosterone antagonist | CHF adjunct; hyperaldosteronism | Primary hyperaldosteronism | 2 mg/kg PO SID–BID | 2–4 mg/kg PO BID |
| Digoxin | Cardiac glycoside | AF rate control; SVT | SVT/AF (rarely; avoid if possible) | 0.005–0.011 mg/kg PO BID (max 0.375 mg/day) | 0.007–0.01 mg/kg PO q48h |
| Sotalol | Class II + III antiarrhythmic | VT (Boxer ARVC), AF, SVT | VT, HCM arrhythmias | 1–3.5 mg/kg PO BID | 1–2 mg/kg PO BID |
References:
- Plumb DC. Plumb's Veterinary Drug Handbook, 9th ed. Wiley-Blackwell, 2018
- Ettinger SJ, Feldman EC, Côté E. Textbook of Veterinary Internal Medicine, 8th ed. Elsevier, 2017
- Atkins C et al. ACVIM consensus guidelines on MVD in dogs. J Vet Intern Med 2019;33:1127–1140
- Boswood A et al. Effect of pimobendan in dogs with preclinical MVD (EPIC Trial). J Vet Intern Med 2016;30:1765–1779
- Tilley LP, Smith FWK. The 5-Minute Veterinary Consult: Canine and Feline, 6th ed. Wiley-Blackwell
This is a shared conversation. Sign in to Orris to start your own chat.